Kura Oncology (NASDAQ:KURA) Price Target Raised to $38.00 at Wedbush

Key Points

• Wedbush raised Kura Oncology’s price target to $38 from $36 and maintained an “outperform” rating, implying substantial upside from the stock’s $9.94 opening price. Analysts overall rate the stock “Moderate Buy,” with an average target of $25.62.
• Kura’s latest quarterly results beat expectations: the company reported a loss of $0.77 per share versus the $0.88 consensus estimate, while revenue reached $20.87 million compared with approximately $20.16 million expected.
• Despite improving product momentum and anticipated collaboration revenue, Kura remains deeply unprofitable, posting a negative net margin of 411.19%; major clinical results are not expected until the KOMET-017 study reports topline data in 2028.

Kura Oncology (NASDAQ:KURA - Get Free Report) had its price target lifted by investment analysts at Wedbush from $36.00 to $38.00 in a report issued on Thursday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Wedbush's price objective points to a potential upside of 282.29% from the stock's current price.

Several other research firms also recently commented on KURA. Sanford C. Bernstein set a $24.00 price objective on shares of Kura Oncology in a report on Monday, June 15th. Citigroup reissued a "market outperform" rating on shares of Kura Oncology in a report on Thursday, May 28th. Wells Fargo & Company set a $24.00 target price on Kura Oncology in a research report on Thursday, June 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kura Oncology in a research report on Friday, July 17th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a research note on Thursday, June 4th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $25.62.

Kura Oncology Trading Up 0.1%

Shares of Kura Oncology stock opened at $9.94 on Thursday. The stock has a market capitalization of $882.37 million, a P/E ratio of -2.97 and a beta of 0.38. Kura Oncology has a 52-week low of $6.24 and a 52-week high of $12.49. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.14 and a current ratio of 6.15. The stock's 50-day simple moving average is $10.15 and its 200 day simple moving average is $9.31.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping analysts' consensus estimates of ($0.88) by $0.11. The firm had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. As a group, research analysts anticipate that Kura Oncology will post -3.45 EPS for the current year.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of the firm's stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the transaction, the insider directly owned 182,345 shares of the company's stock, valued at $1,790,627.90. This trade represents a 31.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kura Oncology

Several large investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in shares of Kura Oncology in the 2nd quarter valued at about $115,286,000. Suvretta Capital Management LLC grew its holdings in shares of Kura Oncology by 5.7% during the fourth quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company's stock worth $89,099,000 after purchasing an additional 459,422 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Kura Oncology by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company's stock worth $57,224,000 after purchasing an additional 39,105 shares during the last quarter. Armistice Capital LLC increased its position in shares of Kura Oncology by 5.7% in the fourth quarter. Armistice Capital LLC now owns 4,936,000 shares of the company's stock worth $51,285,000 after purchasing an additional 264,000 shares during the last quarter. Finally, State Street Corp raised its stake in Kura Oncology by 47.5% in the fourth quarter. State Street Corp now owns 4,931,090 shares of the company's stock valued at $51,234,000 after purchasing an additional 1,587,959 shares in the last quarter.

Kura Oncology News Roundup

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KOMZIFTI momentum strengthened. The acute myeloid leukemia treatment generated $9.1 million in net product revenue, a 57% increase from the first quarter, while new patient starts rose 35% to approximately 115. This commercial growth suggests increasing adoption of Kura’s marketed product. Kura Oncology Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Financial results exceeded expectations. Kura reported a second-quarter loss of $0.77 per share, narrower than the $0.88–$0.89 analyst consensus, while revenue of $20.87 million topped expectations of approximately $20.16 million. The earnings beat may be contributing to the stock’s strength. Kura Oncology Reports Q2 Loss and Beats Revenue Estimates
• Positive Sentiment: Collaboration revenue is expected to provide additional support. Management outlined approximately $90 million to $110 million of collaboration revenue for 2027, improving the company’s medium-term financial visibility. Kura Outlines 2027 Collaboration Revenue
• Neutral Sentiment: Clinical catalysts remain longer term. Kura is targeting topline results from the KOMET-017 study in 2028, leaving investors dependent on commercial execution and collaboration revenue in the nearer term. Kura Oncology Q2 2026 Earnings Call Transcript
• Negative Sentiment: Kura remains deeply unprofitable. Despite beating estimates, the company posted a substantial quarterly loss, with a reported negative net margin of 411.19%. Continued operating losses could limit valuation upside until product and collaboration revenue scale further. Kura Oncology Q2 2026 Earnings Call Summary

About Kura Oncology

Kura Oncology, Inc NASDAQ: KURA is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source